In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.
Innovative berry-based skin spray targets hospital-acquired bacteria
VTT has developed a skin spray, based on nanocellulose and antimicrobial compounds from wild berries, which can be used to treat wounds and eliminate hospital-acquired
August 28, 2024